Supreme Court Passes on Skinny Labeling Case: What Does This Mean for Patients?

Supreme Court Passes on Skinny Labeling Case: What Does This Mean for Patients?

In mid-May, the U.S. Supreme Court opted not to take up a patent-infringement case between two pharmaceutical companies – Teva and GlaxoSmithKline (GSK). While it largely went unnoticed among those who are not patent lawyers, IP nerds, or drug companies, the decision’s ripple effects could have a negative impact for patients across the country looking to get access to newer, better treatments.

read more
FROM OUR ADVISORY BOARD: Are We On the Cusp of a New Drug Pricing Paradigm?

FROM OUR ADVISORY BOARD: Are We On the Cusp of a New Drug Pricing Paradigm?

We may be on the verge of a titanic shift in how drug prices are set. It’s been led by a dramatic decline in insulin prices, but it’s spreading to other brand drugs as well. This new paradigm is the unintended but welcome result of legislative, regulatory, and market pressures exerted on the biopharmaceutical industry.

read more
OP-ED: Promising New Alzheimer’s Drug Calls for CMS to Rethink Access Restrictions .

OP-ED: Promising New Alzheimer’s Drug Calls for CMS to Rethink Access Restrictions .

Some of the most exciting advances in science and medicine are happening in Alzheimer’s, a disease that is one of the greatest epidemics of this generation. Eli Lilly announced promising results last week for experimental amyloid-targeting drug donanemab. These clinical trial results showed that the drug can slow cognitive and functional decline for people with early-stage Alzheimer’s disease. 

read more
Group Purchasing Organizations Impact Access to Medications, Increase Drug Shortages

Group Purchasing Organizations Impact Access to Medications, Increase Drug Shortages

Drug shortages can be a matter of life and death. Sometimes, a shortage may simply require patients to temporarily pay a higher price or shop around to different local pharmacies to find one that has their prescription in stock. But, in the worst cases, a shortage means patients are entirely unable get access to a potentially lifesaving drug at any price.

read more
OP-ED: The Cold War at HHS

OP-ED: The Cold War at HHS

 by MacKay Jimeson   There is an interagency cold war between the Food and Drug Administration and the Centers for Medicare and Medicaid Services at the Department of Health and Human Services. FDA wants to approve promising treatments for patients faster.  CMS...

read more